https://doi.org/10.4081/itjm.2011.82

The pharmacology and activity of non-steroidal anti-inflammatory drugs (NSAIDs): a review of their use as an adjuvant treatment in patients with HBV and HCV chronic hepatitis

Vol. 5 No. 2 (2011)
Submitted: 7 March 2013
Accepted: 7 March 2013
Published: 7 March 2013
Prostaglandin E2, Hepatitis B Virus, Hepatitis C Virus, Chronic hepatitis, Non-steroidal antiinflammatory drugs (NSAIDs).
Abstract Views: 973
PDF: 953
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Sirio Fiorino
sirio.fiorino@ausl.bologna.it
Carmela Cursaro
Stefania Lorenzini
Elisabetta Loggi
Lucia Brodosi
Laura Cattani
Andrea Cuppini
Mauro Bernardi
Pietro Andreone
Introduction: Different DNA and RNA viruses exploit common strategies to support their persistence and replication in infected individuals. In particular, the hepatitis B virus (HBV) and the hepatitis C virus (HCV) cause major health problems worldwide. These pathogens exert an immunosuppressive role by inducing the persistent activation of cyclooxygenase-2 (COX-2) and an increased synthesis of prostaglandin E2 (PGE2). The suppression of this proinflammatory network by non-steroidal anti-inflammatory drugs (NSAIDs) has been proposed as a therapeutic approach to decrease viral replication.
Materials and methods: In this review, the role of inflammation in the support of viral replication and NSAIDs and ketoprofen pharmacology are briefly discussed. In addition, studies that have investigated the use of NSAIDs for the treatment of HBV and HCV chronic hepatitis, which were identified by a systematic literature search of PubMed and MEDLINE, are reported.
Results: To date, pegylated-interferon (PEG-IFN) and/or nucleot(s)ide analogues and PEG-IFN and ribavirin remain the standard therapy for HBV and HCV chronic hepatitis, respectively.
Discussion: The use of NSAIDs in patients with chronic viral hepatitis has only a €˜â€˜historical'' interest. Nevertheless, the possible usefulness of ketoprofen with PEG-IFN and ribavirin for HCVinfected patients, non-responders to standard therapy or with genotype 1, should be evaluated in future clinical studies.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

PlumX Metrics

PlumX Metrics  provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

Fiorino, S., Cursaro, C., Lorenzini, S., Loggi, E., Brodosi, L., Cattani, L., Cuppini, A., Bernardi, M., & Andreone, P. (2013). The pharmacology and activity of non-steroidal anti-inflammatory drugs (NSAIDs): a review of their use as an adjuvant treatment in patients with HBV and HCV chronic hepatitis. Italian Journal of Medicine, 5(2), 82–89. https://doi.org/10.4081/itjm.2011.82

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.